Skip to content

Study · Animal study (in vivo) · rat · 1985

5 results

Cerebral sites of central action of dermorphin on intestinal motility in the rat.

Parolaro D, Sala M, Crema G, Giagnoni G, Gori E

Peptides1 Jan 1985Cited by 7 (Europe PMC)

PMID3831959 (opens in a new tab)DOI10.1016/0196-9781(85)90366-3 (opens in a new tab)PepBankPUB-03831959
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin in the periaqueductal gray matter completely inhibited intestinal propulsion.

    In plain wordsIn rats, dermorphin in the periaqueductal gray matter completely inhibited intestinal propulsion.

    Peptide
    Dermorphin
    Outcome
    DecreaseIntestinal propulsion
    Study

    ratn: not reported in source

    rat
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.4 nmoles/rat · microinjection into periaqueductal gray matterAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin (DM), microinjected at 0.4 nmoles/rat into various sites of the periaqueductal gray matter (PAG), provokes complete inhibition of intestinal propulsion always coupled with full analgesia and catalepsy.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin in the periaqueductal gray matter produced full analgesia.

    In plain wordsIn rats, dermorphin in the periaqueductal gray matter produced full pain relief.

    Peptide
    Dermorphin
    Outcome
    IncreaseAnalgesia
    Study

    ratn: not reported in source

    rat
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    0.4 nmoles/rat · microinjection into periaqueductal gray matterAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin (DM), microinjected at 0.4 nmoles/rat into various sites of the periaqueductal gray matter (PAG), provokes complete inhibition of intestinal propulsion always coupled with full analgesia and catalepsy.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, dermorphin in the periaqueductal gray matter produced catalepsy.

    In plain wordsIn rats, dermorphin in the periaqueductal gray matter produced catalepsy.

    Peptide
    Dermorphin
    Outcome
    IncreaseCatalepsy
    Study

    ratn: not reported in source

    rat
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    0.4 nmoles/rat · microinjection into periaqueductal gray matterAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin (DM), microinjected at 0.4 nmoles/rat into various sites of the periaqueductal gray matter (PAG), provokes complete inhibition of intestinal propulsion always coupled with full analgesia and catalepsy.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, lateral and medial hypothalamus and mid-line thalamus were sensitive to the reported dermorphin effects.

    In plain wordsIn rats, the hypothalamic and thalamic sites were sensitive to the reported dermorphin effects.

    Peptide
    Dermorphin
    Outcome
    Not applicableEffects at hypothalamic and thalamic sites
    Study

    ratn: not reported in source

    rat
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · central brain administrationAs given in this study (rat).

    Source sentences

    Summary
    Finally, some other central brain regions were found sensitive to DM for the above effects such as the lateral and medial hypothalamus and mid-line thalamus.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, dermorphin produced negative results at supraoptic nuclei and the postero-medial cortical amygdaloid nucleus.

    In plain wordsIn rats, dermorphin produced negative results at the supraoptic and specified amygdaloid sites.

    Peptide
    Dermorphin
    Outcome
    No significant changeEffects at supraoptic and amygdaloid sites
    Study

    ratn: not reported in source

    rat
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · central brain administrationAs given in this study (rat).

    Source sentences

    Summary
    Negative results were obtained for the supraoptic nuclei and postero-medial cortical amygdaloid nucleus.
    1 context sentence
    Summary · context
    Finally, some other central brain regions were found sensitive to DM for the above effects such as the lateral and medial hypothalamus and mid-line thalamus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.